Work

Supplementary Figure from Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer

Year: 2023

Type: supplementary-materials

Abstract: Supplementary Figure from Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer

DOI: 10.1158/1078-0432.22486314

Authors: Felipe Batalini, Niya Xiong, Nabihah Tayob, Madeline Polak, Julia Eismann, Lewis C. Cantley, Geoffrey I. Shapiro, Viktor Adalsteinsson, Eric P. Winer, Panagiotis A. Konstantinopoulos, Alan D'Andrea, Elizabeth M. Swisher, Ursula A. Matulonis, Gerburg M. Wulf, Erica L. Mayer

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361812786

Cites:

Cited by:

Related to: 10